Rigel Pharmaceuticals Inc expected to post earnings of 2 cents a share - Earnings Preview

Rigel Pharmaceuticals

02/05/2025 22:13

Rigel Pharmaceuticals Inc RIGL.OQ RIGL.O is expected to show a rise in quarterly revenue when it reports  results on May 6 for the period ending March 31 2025

The South San Francisco California-based  company is expected to report a 48.6% increase in revenue to $43.874 million from $29.53 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Rigel Pharmaceuticals Inc is for earnings of 2 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 27.9% in the last three months. ​

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.50​, above​ its last closing price of $18.72. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.59
0.47
0.80
Beat
71.3
Sep. 30 2024
0.08
0.06
0.70
Beat
1,100.1
Jun. 30 2024
-0.28
-0.29
-0.06
Beat
79.5​
Mar. 31 2024
-0.27
-0.29
-0.50
Missed
-73.4
​​Dec. 31 2023
-0.27
-0.30
0.00
Beat
100
Sep. 30 2023
-0.72
-0.71
-0.30
Beat
57.7​
Jun. 30 2023
-0.78
-0.78
-0.40
Beat
48.7
Mar. 31 2023
-0.95
-0.97
-0.80
Beat
17.9

This summary was machine generated May 2 at 21:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)